Expert Review of Pharmacoeconomics & Outcomes Research最新文献

The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019. 2005-2019年丹麦处方药销售变化与死亡率和医院使用率变化的关系

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-05-03 DOI: 10.1080/14737167.2026.2660761

Frank R Lichtenberg

{"title":"The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019.","authors":"Frank R Lichtenberg","doi":"10.1080/14737167.2026.2660761","DOIUrl":"10.1080/14737167.2026.2660761","url":null,"abstract":"Background: The objective of this study is to investigate the relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark during the period 2005-2019.Research design and methods: We analyze the correlation across diseases between changes in sales of drugs used to treat the disease and changes in mortality or hospital utilization from that disease. Two attributes of the drugs used to treat a disease sold each year are constructed and analyzed. The first is the number of drugs sold; the second is the fraction of drugs that were first sold after 1997 (post-1997).Results: The number of years of life lost before ages 85, 75 and 65 and the number of hospital days due to a disease is significantly inversely related to the share of post-1997 drugs used to treat the disease that were sold in previous years.Conclusion: Assuming that the mortality and hospital utilization changes were caused by the changes in prescription drug sales, the 13% estimated reduction in 2016 inpatient curative care expenditure due to the 2002-2013 increase in the share of post-1997 drugs is 2.5 times as large as 2016 expenditure on prescribed medicines first sold after 1997.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB-IIC melanoma in the United States. 在美国，辅助nivolumab治疗切除的IIB-IIC期黑色素瘤的估计成本效益。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-27 DOI: 10.1080/14737167.2026.2665725

Islam Eljilany, Vakaramoko Diaby

{"title":"Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB-IIC melanoma in the United States.","authors":"Islam Eljilany, Vakaramoko Diaby","doi":"10.1080/14737167.2026.2665725","DOIUrl":"https://doi.org/10.1080/14737167.2026.2665725","url":null,"abstract":"Background: The CheckMate 76K trial analysis showed that the use of nivolumab as adjuvant therapy in the treatment of patients with resected stage IIB-IIC melanoma reduced recurrence-free survival (RFS). This study aimed to estimate the cost-effectiveness of nivolumab as adjuvant therapy in these patients from the United States (U.S.) payer perspective.Research design and methods: A cohort-based Markov model with monthly cycles was developed to simulate RFS over a Five-year base-case horizon. Health states included recurrence-free without adverse events, recurrence-free with adverse events, and disease recurrence (absorbing). Transition probabilities were derived from parametric survival models fitted to reconstructed individual patient-level RFS data. Sensitivity and scenario analyses were applied.Results: Over five years, nivolumab increased costs by USD 182,783 and yielded 0.444 additional quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio (ICER) of USD 411,958 per QALY. Nivolumab was not cost-effective at conventional U.S. willingness-to-pay thresholds in the base case. Sensitivity analyses confirmed robustness, while scenarios assuming greater durability of benefit improved cost-effectiveness but generally remained above thresholds.Conclusions: Within a conservative recurrence-focused framework, adjuvant nivolumab improves health outcomes but is unlikely to be cost-effective at current prices over a short-term horizon. Reassessment will be essential as longer-term evidence emerges.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-15"},"PeriodicalIF":1.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications. 南非一家由抗菌药物管理的学术医院内社区获得性肺炎的成本和临床分析及其意义。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-26 DOI: 10.1080/14737167.2026.2663891

Katlego Bjang, Madimetje Kutume, Nthabiseng Mongoai, Boitshepo Sebothoma, Rajesh Vagiri, Johanna C Meyer, Brian Godman, Letlhogonolo Makhele

{"title":"Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications.","authors":"Katlego Bjang, Madimetje Kutume, Nthabiseng Mongoai, Boitshepo Sebothoma, Rajesh Vagiri, Johanna C Meyer, Brian Godman, Letlhogonolo Makhele","doi":"10.1080/14737167.2026.2663891","DOIUrl":"10.1080/14737167.2026.2663891","url":null,"abstract":"Background: Pneumonia is a common respiratory infection treated with antibiotics. Patients needing antibiotics risk poor outcomes due to antimicrobial resistance (AMR). In LMIC, inappropriate prescribing is common due to a lack of sufficient diagnostics, leading to empiric prescribing. Antimicrobial stewardship programmes can improve prescribing practices.Research design and methods: A retrospective cohort study reviewing antibiotic prescription charts from May to September 2024 at an academic hospital in South Africa. A treatment pathway model was used to evaluate patients' clinical outcomes.Results: Severe pneumonia was observed in 59.3% of patients, compared with 40.7% with uncomplicated pneumonia, with the majority of severe cases occurring in patients aged 51-75 years (37.5%). The cost of treatment per patient was higher for severe pneumonia (R1,328.12) versus uncomplicated cases (R1,157.40), with labor costs the largest cost component (58%). Severe cases contributed 63% (R63, 749.10) of total treatment costs, while uncomplicated cases accounted for 37% (R38,195.50). The treatment pathway model analysis indicated that hospitalisation rates decreased from 85% on Review Day 3 to 58% on Review Day 7 for severe cases.Conclusion: Higher treatment costs and longer hospital stays were associated with severe pneumonia, underscoring the need for early, appropriate intervention.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-15"},"PeriodicalIF":1.5,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimicrobial resistance as an economic externality: optimal control, Pigouvian taxation, and governance implications. 抗微生物药物耐药性作为一种经济外部性：最优控制、庇古税和治理影响。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-21 DOI: 10.1080/14737167.2026.2659620

Aritra Jana, Debnarayan Khatua, Santi M Mandal

{"title":"Antimicrobial resistance as an economic externality: optimal control, Pigouvian taxation, and governance implications.","authors":"Aritra Jana, Debnarayan Khatua, Santi M Mandal","doi":"10.1080/14737167.2026.2659620","DOIUrl":"10.1080/14737167.2026.2659620","url":null,"abstract":"Background: The rise of antimicrobial resistance (AMR) is a major concern worldwide, with serious implications for health and the economy. Global burden estimates, coupled with mortality projections for 2019, indicate that antimicrobial-resistant infections will cause large-scale deaths and massive economic losses by 2050. AMR is not only about health; It is an economic externality created by misaligned incentives in health, agriculture, and trade.Methods: We present a dynamic endogenous model that captures the interplay among antibiotic use, resistance evolution, and social costs. Optimal fiscal interventions are identified and evaluated using simulation scenarios based on European data, with particular attention to the impact of diverting tax revenue to stewardship and diagnostics.Results: The models demonstrate that, under optimal social conditions, antibiotic use should be reduced by 8.6% relative to private use levels. The combination of around <math><mrow><mrow><mi>$</mi></mrow></mrow><mn>0.775</mn></math> per dose with the Pigouvian tax can be used as a diagnostic and stewardship investment to adjust incentives and build public health power.Conclusion: The study makes a distinct contribution by explicitly incorporating revenue recycling into a dynamic Pigouvian framework, thereby supporting the idea that self-governance benefits from AMR taxation. The solution is then coordinated toward long-term economic planning with intervention in biomedicine against AMR.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.5,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective. 从哥伦比亚医疗保健系统的角度来看，局部晚期或转移性尿路上皮癌患者的新型一线治疗的护理成本和预算影响。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-19 DOI: 10.1080/14737167.2026.2660759

Pieralessandro Lasalvia, Paola Jaramillo, Maycos Zapata, Martin Zapata, Leonor González, Verónica Hernández, Juliana Restrepo

{"title":"Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.","authors":"Pieralessandro Lasalvia, Paola Jaramillo, Maycos Zapata, Martin Zapata, Leonor González, Verónica Hernández, Juliana Restrepo","doi":"10.1080/14737167.2026.2660759","DOIUrl":"10.1080/14737167.2026.2660759","url":null,"abstract":"Background: Locally advanced or metastatic urothelial carcinoma (la/mUC) imposes substantial clinical and economic burden. Novel first-line (1L) therapies have expanded treatment options but may significantly increase healthcare expenditures. Economic evidence in Colombia remains limited, warranting cost and budget impact analyses of 1L therapies from the national payer perspective.Research design and methods: Direct healthcare costs of the first year of treatment were estimated for patients with la/mUC starting 1L treatment: chemotherapy (CT) followed by avelumab+best supportive care (BSC); CT+BSC; nivolumab+CT (NIV+CT); and enfortumab vedotin+pembrolizumab (EV+PEM). Efficacy and safety data were obtained from JAVELIN Bladder 100, CheckMate 901, and EV-302. Costs (Colombian pesos; COP, and United States dollars; USD) were estimated for medication acquisition and administration, disease management, severe adverse events (grade ≥3), and subsequent treatments. Drug costs were obtained from SISMED (2024) and Suficiencia. Budget impact compared a base-case scenario (CT+avelumab+BSC) versus an alternative scenario incorporating EV+PEM and NIV+CT.Results: CT+avelumab+BSC was associated with a total annual cost of COP 271,530,508 (US$ 66,693), 66% less than EV+PEM and 24% less than NIV+CT. Budget impact analysis showed an increase of COP 160,067,748,642 (US$ 39.32 million) (+42.8%).Conclusions: CT+avelumab+BSC had the lowest annual cost, suggesting it is affordable versus EV+PEM and NIV+CT.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.5,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden Tree - a conceptual framework for the burden associated with pediatric infectious diseases: a Delphi approach. 负担树-与儿童传染病相关的负担的概念框架：德尔菲方法。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-05 DOI: 10.1080/14737167.2026.2650164

Cristina Carias, Danielle Riley, Amanda L Eiden, Ashley L Enstone, Isabelle J Whittle, Deanna B Marshall, Charlotte W Oswald, J Mick Tilford

{"title":"Burden Tree - a conceptual framework for the burden associated with pediatric infectious diseases: a Delphi approach.","authors":"Cristina Carias, Danielle Riley, Amanda L Eiden, Ashley L Enstone, Isabelle J Whittle, Deanna B Marshall, Charlotte W Oswald, J Mick Tilford","doi":"10.1080/14737167.2026.2650164","DOIUrl":"10.1080/14737167.2026.2650164","url":null,"abstract":"Background: Accurate economic evaluations require capturing the full value of health interventions, yet broader impacts are often inconsistently represented. This study developed and validated the 'Burden Tree'- a conceptual framework to comprehensively capture the burden of pediatric infectious diseases on patients and families.Methods: A double-blind modified-Delphi panel was conducted with 21 experts from the US and Europe in pediatric infectious diseases. The process, informed by targeted literature review and expert input, involved two rounds of online surveys and a virtual consensus meeting to elicit and validate categories, elements, and sub-elements of the Burden Tree.Results: Burden Tree categories included direct medical and non-medical costs, productivity losses, and impact on quality of life, each differentiating elements before, during, and after the episode. Validated sub-elements covered costs related to hospitalizations, drugs, visits, tests, healthcare transport, caregiver bereavement or exhaustion; housing modifications, special accommodations and resources for sequelae; caregiver and patient absenteeism and presenteeism, caregiver employment termination; caregiver and patient changes in health-related quality of life, and discrimination following the episode. The panel agreed the Burden Tree categories were comprehensive, mutually exclusive, and customizable.Conclusion: This modified-Delphi panel validated a comprehensive and mutually exclusive framework for economic evaluation inclusion.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.5,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia. 马来西亚医疗保健专业人员对药物经济学的知识、认知和应用。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-02 DOI: 10.1080/14737167.2026.2651882

Haarathi Chandriah, Ee Vien Low, Nur Sufiza Ahmad, Azmi Nor Mohd Farez Ahmat, Izzati Mohd Farok, Jacqueline Hui Yi Wong, Weng Hong Fun, Subramaniam Thanimalai, Chin Hui Ng, Nor Haizan Ibrahim, Mohd Rozaini Rosli, Kenneth Lik Chien Lim, Yai Wen Choo

{"title":"Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia.","authors":"Haarathi Chandriah, Ee Vien Low, Nur Sufiza Ahmad, Azmi Nor Mohd Farez Ahmat, Izzati Mohd Farok, Jacqueline Hui Yi Wong, Weng Hong Fun, Subramaniam Thanimalai, Chin Hui Ng, Nor Haizan Ibrahim, Mohd Rozaini Rosli, Kenneth Lik Chien Lim, Yai Wen Choo","doi":"10.1080/14737167.2026.2651882","DOIUrl":"10.1080/14737167.2026.2651882","url":null,"abstract":"Background: Pharmacoeconomics (PE) is essential in optimizing healthcare resource allocation and ensuring cost-effective treatment decisions. Despite its recognized importance, limited evidence exists regarding healthcare professionals' understanding and application of PE in Malaysia. This study assessed the knowledge, perception, and application of PE among healthcare professionals within the Ministry of Health (MOH) Malaysia.Methods: A cross-sectional online survey was conducted among MOH healthcare professionals. The survey captured demographic characteristics, familiarity with PE, self-reported knowledge, perception of its importance, and its application in clinical and formulary decision-making. Descriptive statistics were used to summarize the findings.Results: A total of 754 respondents completed the survey, comprising pharmacists (71.5%), doctors (24.3%) and other healthcare professionals (4.2%). While 63.7% reported familiarity with PE, substantial knowledge gaps were observed, particularly in cost-utility and cost-effectiveness analyses. PE application was most prevalent in budget impact assessments for formulary decisions. Notably, 94.8% of Drug and Therapeutics Committee members recognized the importance of PE in decision-making, and 96.9% supported the need for dedicated personnel with PE competency.Conclusion: PE knowledge and application varied across MOH healthcare professionals, underscoring the need for targeted training and capacity building to strengthen PE competency, ultimately supporting evidence-informed, cost-effective healthcare decision-making in Malaysia.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medication adherence research: expert perspectives on key HEOR trends for 2026. 药物依从性研究：专家对2026年HEOR关键趋势的看法。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-27 DOI: 10.1080/14737167.2026.2650160

Tamas Agh, Bijan Borah, Marcia Vervloet, Mickael Hiligsmann

引用次数: 0

Net benefits of investing in pulse oximetry and oxygen for childhood pneumonia in high burden countries. 在高负担国家投资脉搏血氧仪和供氧治疗儿童肺炎的净效益。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-27 DOI: 10.1080/14737167.2026.2650165

Tim Colbourn, Carina King

引用次数: 0

Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran. 伊朗初级保健机构即时护理A1C检测的成本-效果分析

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-26 DOI: 10.1080/14737167.2026.2650163

Abdoreza Mousavi, Mehdi Raadabadi, Ali Darvishi

{"title":"Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran.","authors":"Abdoreza Mousavi, Mehdi Raadabadi, Ali Darvishi","doi":"10.1080/14737167.2026.2650163","DOIUrl":"10.1080/14737167.2026.2650163","url":null,"abstract":"Background: Given the critical role of timely monitoring in diabetes management, effective and accessible testing strategies are increasingly vital. This study evaluated the cost-effectiveness of point-of-care A1c (POC-A1c) testing compared with traditional laboratory-based A1c testing in primary care settings in Iran.Research design and methods: A lifetime (40 year) Markov model was developed to estimate expected costs (valued in 2023 PPP-adjusted US dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) for the two strategies. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainty in key model parameters.Results: POC-A1C was associated with an incremental cost of US$1,647.76 and a 0.15 QALY gain versus traditional laboratory testing, yielding an ICER of US$10,717.27 per QALY. Consequently, it was cost-effective at a willingness-to-pay threshold equal to Iran's 2023 per capita GDP. Also, based on probabilistic sensitivity analysis, the probability of POC-A1C being cost-effective was 58%.Conclusions: These findings suggest that integrating POC-A1c testing into primary care may represent a valuable strategy for strengthening diabetes management in Iran. While associated with higher direct costs, its potential to improve glycemic control and long-term health outcomes supports consideration by policymakers, particularly in the context of expanding access to timely diabetes monitoring.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0